Transce3nd »

Adaptimmune Therapeutics shares owned by Transce3nd

Quarter-by-quarter ownership of Adaptimmune Therapeutics (ADAP) shares owned by Transce3nd from 13F filings

Historical chart of Transce3nd investment in Adaptimmune Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Adaptimmune Therapeutics held by Transce3nd consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Adaptimmune Therapeutics by Transce3nd

Quarter filed Position value Share count Share price at filing
2025-06-30 $42 175 0.24
2025-03-31 $34 175 0.19
2024-12-31 $93 175 0.54

More positions owned by Transce3nd

Spdr S&p 500 Etf Tr Tr Unit Etf (SPY)
State Street Spdr Portfolio S&p 500 Etf Etf (SPLG)
Weitz Core Plus Income Fund Inst'l Class M (WCPBX)
Cibus C (CBUS)
Vanguard Federal Money Mkt Fund Investor Class MM (VMFXX)
Fullerthaler Behavioral Small-mid Core Equity Fd Inst'l Class M (FTSIX)
Vanguard Total Stock Market Vipers Etf (VTI)
St Spdr S&p Wld Xus Etf (SPDW)
Regan Capital Total Return Income Fund Institutional Class M (RCIRX)
Aqr Long-short Equity Fund Class I M (QLEIX)
River Canyon Total Return Bond Fund Inst'l Class M (RCTIX)
Oakmark Oakmark Fund Inst'l Class M (OANMX)
Blackrock Systematic Multi Strategy Fund Inst'l Class M (BIMBX)
Eaton Vance Global Macro Abs Ret Adv Fund Class I M (EGRIX)
J P Morgan Exchange-traded Etf (JEPI)

View all positions for Transce3nd

Top funds holding Adaptimmune Therapeutics

Long Focus Capital Management
UBS Group
Morgan Stanley
Renaissance Technologies
Jane Street
Acadian Asset Management
Empirical Finance
National Asset Management
Rathbones Brothers
FMR
Susquehanna International
Citadel Advisors
Lumbard Investment Counseling
Lakeridge Wealth Management
XTX Topco

View all funds holding Adaptimmune Therapeutics